Psoriasis (Auckland, N.Z.)最新文献

{"title":"Global Trends and Future Predictions of Psoriasis Burden: Insights from the GBD 2021 Study.","authors":"Xiaoyu Gu, Xinquan Wang, Yang Bin, Ruzeng Xue, Guannan Zhu","doi":"10.2147/PTT.S558419","DOIUrl":"10.2147/PTT.S558419","url":null,"abstract":"<p><strong>Background: </strong>Psoriasis is a common chronic inflammatory skin disorder, and the global burden of psoriasis has not been fully disclosed.</p><p><strong>Methods: </strong>We extracted prevalence, incidence and disability-adjusted life years (DALYs) for psoriasis from 1990 to 2021 in Global Burden of Disease (GBD) and predicted trends in the next 15 years though ARIMA model.</p><p><strong>Results: </strong>Globally, age-standardized incidence rate (ASIR) of psoriasis increased from 57 cases/100,000 people (95% CI: 55.3~58.8) in 1990 to 62 cases/100,000 people (95% CI: 60.1~63.9) in 2021. Age-standardized prevalence rate (ASPR) and age-standardized disability-adjusted life year rate (ASDR) exhibited similar trends of increases. The global ASIR, ASPR, and ASDR for males were significantly higher than females. In 2021, ASIR peaked in the 55-69 ages, while ASPR and ASDR reached peaks between the ages of 65-74. Regionally, ASPR, ASIR, and ASDR in 2021 were highest in high Socio-demographic index (SDI) regions. The highest global regions and countries of ASPR, ASIR and ASDR were Western Europe and Germany, respectively. The East Asia region and Republic of Equatorial Guinea showed most significant growth in these psoriasis indicators since 1990. Furthermore, there was a significant increase in ASIR (8.06%), ASPR (8.14%), and ASDR (13.64%) of global psoriasis over the next 15 years.</p><p><strong>Conclusions: </strong>Global burden of psoriasis is expected to continuously increase, and strengthening risk-factor management and prioritizing high-risk subgroups (males, elderly, high SDI regions and Western Europe, etc) will be essential for region-specific strategies and future healthcare planning.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"15 ","pages":"569-580"},"PeriodicalIF":5.2,"publicationDate":"2025-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12744867/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145859563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antibodies Targeting Gasdermin E as a Potential Therapeutic Option for Psoriasis - A Pilot Study on a Mouse Model.","authors":"Julia Nowowiejska-Purpurowicz, Justyna M Hermanowicz, Dariusz Pawlak, Iwona Flisiak, Tomasz Lipinski","doi":"10.2147/PTT.S567601","DOIUrl":"10.2147/PTT.S567601","url":null,"abstract":"<p><strong>Background: </strong>Psoriasis is a frequent and complex dermatosis of uncertain origin. A few years ago, a family of gasdermin proteins was implicated in psoriasis pathogenesis. Although the number of therapeutic options for psoriasis is growing, considering the burden of the disease, treatment personalization, and the possibility of side effects or loss of the drug's efficacy, it is important to seek new therapeutic targets.</p><p><strong>Objective: </strong>The aim of this study was to assess the efficacy of antibodies against gasdermin E (GSDME) in the treatment of psoriatic lesions.</p><p><strong>Methods: </strong>The study involved 30 male BALB/c mice, 8 weeks old. 5% imiquimod cream was applied topically on the skin to induce psoriatic lesions. The next day after the psoriatic lesions appeared, the antibodies were administered. Mice from the study group received the rabbit polyclonal anti-GSDME antibody intravenously or intraperitoneally. The control group was administered sterile 0.9% saline solution.</p><p><strong>Results: </strong>The injection of anti-GSDME antibodies to mice with imiquimod-induced psoriasis resulted in the resolution of skin lesions, whereas the injection of saline to the control group did not result in significant changes.</p><p><strong>Conclusion: </strong>Antibodies targeting GSDME seem to be promising therapeutic agents in psoriasis; however, their utility has to be confirmed in future studies.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"15 ","pages":"561-567"},"PeriodicalIF":5.2,"publicationDate":"2025-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12722015/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145822392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PEGylated Peptide for Targeted Inhibition of Human Antigen R as a Novel Therapeutic Strategy for Psoriasis: A Proof-of-Concept Study.","authors":"Yu-Fon Chen, Yi-Sheng Jiang, Yi-Cheng Chen, Chien-Hsiang Chang, Jeng-Shiung Jan","doi":"10.2147/PTT.S563589","DOIUrl":"10.2147/PTT.S563589","url":null,"abstract":"<p><strong>Introduction: </strong>Psoriasis, characterized by dermatological manifestations, exhibits a systemic impact through its association with serious comorbidities, including inflammatory arthritis, cardiovascular and metabolic diseases, and psychiatric disorders. Current high-cost traditional therapies primarily involve antibodies against psoriasis-associated cytokines. Human antigen R (HuR), an RNA-binding protein that regulates the expression of upstream inflammatory cytokines, is overexpressed in immune disorders. Oligopeptide-based drugs that specifically interact with proteins to block downstream gene expression via structural interactions have garnered significant attention. In this study, we report a peptide-based polymer to target HuR and evaluated their efficacy in treating imiquimod (IMQ)-induced psoriasis-like dermatitis in mice ears.</p><p><strong>Methods: </strong>Specifically, the HuR-inhibiting peptide (HIP) is PEGlated to obtain methoxypolyethylene glycol-<i>block</i>-poly(γ-benzyl glutamate) (mPEG-<i>b</i>-PBLG) amphiphilic block copolymer. The self-assembly of the mPEG-<i>b</i>-PBLG block copolymer facilitates the formation of polymeric nanoparticles (NPs) in aqueous solutions, resulting in the improvement of the stability and bioactivity of the oligopeptide.</p><p><strong>Results: </strong>Macroscopic and histological analyses demonstrated that the oligopeptide significantly alleviates the symptoms in psoriasis model mice. Furthermore, the levels of the key cytokine IL-23 and the growth factor VEGF are downregulated. Notably, the HIP effectively targeted the ear skin and did not induce apparent organotoxicity.</p><p><strong>Discussion: </strong>The promising results demonstrated in this proof-of-concept study provide strong evidence supporting the targeted inhibition of HuR via PEGylated peptide. The observed efficacy in mitigating key inflammatory markers (VEGF and IL-23) highlights the potential of this approach to offer superior specificity and reduced systemic side effects compared to current broad-spectrum immunosuppressants. This HuR-targeting strategy offers a potentially low-cost and effective therapeutic approach for psoriasis patients.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"15 ","pages":"545-559"},"PeriodicalIF":5.2,"publicationDate":"2025-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12676014/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145703174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neurofunctional Reversibility in Psoriasis Vulgaris After IL-17A Inhibition: A Resting-State fMRI and Neurocognitive Analysis.","authors":"Jiayun Liu, Huiping Fan, Rui Sun, Yunyan Pang, Xiaojin Li, Qingsong Ma, Chen Xu, Dong Zhang, Weiyuan Ma","doi":"10.2147/PTT.S554255","DOIUrl":"10.2147/PTT.S554255","url":null,"abstract":"<p><strong>Purpose: </strong>Interleukin-17A (IL-17A) drives psoriasis and central nervous system neuroinflammation, but clinical research on whether IL-17A-targeted biotherapy modulates brain activity to improve neuropsychiatric outcomes in psoriasis is lacking. This study aims to investigate brain functional changes, cognitive impairment, and the effects of IL-17A monoclonal antibody therapy in psoriasis vulgaris.</p><p><strong>Patients and methods: </strong>Regular secukinumab treatment. Meanwhile, 20 healthy controls (HCs) matched in age and gender were enrolled. The patients underwent functional magnetic resonance imaging (fMRI) before treatment and 48 weeks after treatment. The healthy controls also had fMRI scans. It assessed clinical data, cognition/neuropsych status (MoCA, SDS, SAS), disease severity/quality of Life (PASI/DLQI), and brain function via rs-fMRI (ALFF/ReHo).</p><p><strong>Results: </strong>Compared to healthy controls, the psoriasis vulgaris patients showed increased ALFF in the frontal lobe, as well as increased frontal ReHo. The treatment group showed signal recovery in some brain regions. Patients before treatment had lower MoCA scores vs controls (<i>P</i> < 0.001)) and higher SAS/SDS scores (SAS, <i>P</i> < 0.0001; SDS, <i>P</i> < 0.05). Patients after treatment showed higher MoCA scores vs before treated (<i>P</i> < 0.05), similar to controls, with lower SAS scores (<i>P</i> < 0.0001) and reduced PASI/DLQI (<i>P</i> < 0.0001).</p><p><strong>Conclusion: </strong>Psoriasis is associated with brain dysfunction and neuropsychiatric symptoms. IL-17A antibody therapy improves skin symptoms, restores brain function, and alleviates neuropsychiatric issues vs untreated patients, supporting multidimensional treatment.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"15 ","pages":"535-543"},"PeriodicalIF":5.2,"publicationDate":"2025-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12584804/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145454222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors of Successful Secukinumab Dose Tapering in Moderate-to-Severe Psoriasis: A Retrospective Study.","authors":"Jiawen Chen, Zhixun Xiao, Xueting Zeng, Niu Xiang, Renwei Luo, Rongying Chen, Beiqi Lin, Hui Ke, Ting Gong, Chao Ji","doi":"10.2147/PTT.S531447","DOIUrl":"10.2147/PTT.S531447","url":null,"abstract":"<p><strong>Background: </strong>Psoriasis (PsO) is a prevalent chronic disease affecting millions, with biologic therapies like secukinumab showing efficacy. With the extensive and prolonged use of secukinumab, identifying strategies for successful dose tapering has emerged as a recent challenge.</p><p><strong>Objective: </strong>This retrospective study aims to identify predictors of successful secukinumab dose tapering in patients with moderate-to-severe plaque psoriasis.</p><p><strong>Methods: </strong>This retrospective study included patients who received secukinumab 300 mg weekly for 5 weeks, then every 4 weeks, achieving and maintaining Psoriasis Area and Severity Index (PASI) 90 for ≥6 months. Statistical analyses included the Mann-Whitney <i>U</i>-test, Friedman M test, and logistic regression (<i>P</i><0.05).</p><p><strong>Results: </strong>Among the 75 secukinumab-treated patients, 40 (53.33%) successfully tapered their dosage. BMI, dose tapering timing, and pre-tapering treatment duration were significant predictors of tapering success. Seasonal effects were observed, with autumn and winter attempts having an increased risk of failure. PASI 75 and PASI 90 rates dropped from week 6 to 12, with no serious adverse events.</p><p><strong>Conclusion: </strong>Lower BMI, dose tapering initiation in spring and summer, and rapid PASI 90 achievements are associated with successful secukinumab dose tapering. These findings suggest that, under appropriate clinical conditions, dose tapering may be a feasible strategy to maintain disease control while potentially reducing treatment-related costs and minimizing the risk of adverse effects.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"15 ","pages":"527-534"},"PeriodicalIF":5.2,"publicationDate":"2025-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12540611/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145357165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the Role of Disease Duration in Systemic Therapy Response Among Patients with Moderate-to-Severe Psoriasis.","authors":"Min Dai, Yuxiong Jiang, Yujing Xi, Lezhen Xu, Dawei Huang, Yu Wang, Yifan Hu, Qian Yu, Yuling Shi","doi":"10.2147/PTT.S544568","DOIUrl":"10.2147/PTT.S544568","url":null,"abstract":"<p><strong>Background: </strong>Psoriasis is a chronic immune-mediated inflammatory disease. Systemic therapy is usually applicable to patients who have failed topical treatment or phototherapy, but the value of early systemic therapy remains unclear.</p><p><strong>Purpose: </strong>This study aimed to evaluate the impact of disease duration on the clinical efficacy and patients reported outcomes in moderate to severe psoriasis patients treated with systemic agents.</p><p><strong>Methods: </strong>Our research was based on the SPEECH, an observational, prospective, multicenter registry. Adult patients with moderate to severe psoriasis receiving systemic therapy (including biologics, methotrexate or acitretin) were divided into groups based on disease duration: <2 years, 2~10 years, and ≥10 years. The clinical efficacy was assessed using PASI (Psoriasis Area and Severity Index), BSA (Body Surface Area), PGA (Physician Global Assessment). The Dermatology Life Quality Index (DLQI), PtGA (Patient Global Assessment) and the Hospital Anxiety and Depression Scale (HADS) were used to assess the patients reported outcomes. The treatment outcomes were analyzed at 3 months and 6 months. Using multiple logistic regression to analyze the differences between patients with different disease duration, and conducting subgroup analysis and sensitivity analysis to test the robustness of the research results.</p><p><strong>Results: </strong>A total of 1908 patients who met the criteria were included in the analysis. After 3 months of treatment, the PASI75 response rates for the three groups of patients (<2 years, 2-10 years, and ≥10 years) were 55%, 55% and 60%, respectively all <i>p</i> value >0.05. No significant differences were observed among the three groups in the rates of achieving BSA <1/3, PGA 0/1, DLQI 0/1, PtGA 0/1, HADS-A = 0, and HADS-D = 0. Notably, these outcomes still showed no significant differences at 6 months. Subgroup and sensitivity analyses also yielded consistent results.</p><p><strong>Conclusion: </strong>Disease duration does not significantly affect clinical efficacy or patients reported outcomes in patients with moderate-to-severe psoriasis receiving systemic therapy. These results indicate that early systemic therapy does not improve treatment outcomes in real clinical settings, thereby supporting the continued efficacy of step-up treatment strategy and providing novel insights into clinical practice management.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"15 ","pages":"513-525"},"PeriodicalIF":5.2,"publicationDate":"2025-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12533492/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145330825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrated Single-Cell RNA Sequencing and Proteome-Wide Mendelian Randomization Identifies Therapeutic Targets for Psoriasis and Associated Complications.","authors":"Ping Zheng, Yanyun Cao, Ao Wang, Ke Yi","doi":"10.2147/PTT.S535791","DOIUrl":"10.2147/PTT.S535791","url":null,"abstract":"<p><strong>Background: </strong>To identify new targets for protein-based treatments in psoriasis and evaluate the possible negative impacts of these druggable proteins.</p><p><strong>Methods: </strong>We carried out an extensive analysis of the entire set of proteins in the blood (proteome-wide) to determine if there are causal links between certain blood proteins and the likelihood of developing psoriasis. The proteins were selected from the UK Biobank Pharma Proteomics Project (UKBPPP) database, which includes genetic data for 2,940 different blood proteins. We obtained the cis-expression quantitative trait locus (cis-eQTL) of druggable genes from eQTLGen Consortium as exposure and the genome-wide association study (GWAS) of psoriasis.</p><p><strong>Results: </strong>Our research discovered a strong genetic link between plasma APOF, ATP6V1G2, IFNLR1, CRELD1, PRSS8, and TNF proteins and a higher chance of having psoriasis. These proteins share genetic variations associated with psoriasis (PPH3+PPH4>0.8). The ROC curves derived from these protein quantity trait loci (pQTLs) demonstrate that they can distinguish between individuals with psoriasis and those without. The druggable gene analysis showed that simvastatin is related to TNF based on the Drug SIGnatures DataBase webtool.</p><p><strong>Conclusion: </strong>Our study has explored the causal relationships between six blood proteins and psoriasis, offering a detailed insight into potential therapeutic targets. Among them, simvastatin might have an effect on psoriasis via TNF.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"15 ","pages":"501-511"},"PeriodicalIF":5.2,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12519998/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145304798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Codon-Usage Bias and Genomic Architecture of 79 Psoriasis-Susceptibility Genes: Implications for Expression Efficiency and Therapeutic Targeting.","authors":"Shanshan Jiang, Lu Chen, Jianghui Li, Fei Gao, Xiaoning Yan, Yiding Zhao","doi":"10.2147/PTT.S545695","DOIUrl":"10.2147/PTT.S545695","url":null,"abstract":"<p><strong>Introduction: </strong>Psoriasis is a chronic autoimmune skin disorder with a complex genetic basis. However, the codon usage patterns and nucleotide features of psoriasis-related genes remain unexplored, despite their potential to influence gene expression and disease progression.</p><p><strong>Methods: </strong>We analyzed 79 psoriasis-associated genes to investigate codon usage bias (CUB) and nucleotide composition. Metrics included GC content, effective number of codons (ENC), and relative synonymous codon usage (RSCU). Evolutionary influences were assessed using correspondence analysis, parity rule 2 (PR2) plots, and neutrality plots.</p><p><strong>Results: </strong>Functional enrichment analysis identified pathway involvement. Comparative genomic analysis evaluated differences in coding sequence and UTR lengths and GC content relative to the genome-wide background. Psoriasis-related genes showed high GC content (mean = 53.3 ± 9.3%) with a strong preference for GC-ending codons, especially at the third codon position (GC3 = 60.6 ± 16.1%). RSCU analysis revealed frequent use of GCC (alanine), CTG (leucine), and GTG (valine). While the mean ENC (46.2 ± 9.9) suggested moderate codon bias, several genes displayed strong bias (ENC < 30). Selection pressure accounted for 71% of codon usage variation, with mutation pressure contributing 29%. Functional enrichment showed significant involvement in IL-17 (FDR = 3.4×10^-3), JAK-STAT (FDR = 3.4×10^-3), and TNF (FDR = 8.0×10^-³) signaling pathways. These genes also tended to have shorter coding sequences and 5'UTRs and higher GC content compared to genome-wide averages.</p><p><strong>Conclusion: </strong>In conclusion, this study reveals that psoriasis-related genes are under strong selective pressure, enriched in key inflammatory pathways, and exhibit codon and nucleotide features that may optimize expression in inflamed tissues. These insights have translational relevance for designing codon-optimized mRNAs, gene therapies, and diagnostic tools tailored to autoimmune diseases like psoriasis.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"15 ","pages":"479-499"},"PeriodicalIF":5.2,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12478602/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145202404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vunakizumab for Treatment of Acrodermatitis Continua of Hallopeau: A Case Report and Literature Review.","authors":"Yi Yao, Yingming Ma, Huajie Zhong, Feiying Guo, Jiling Zhu, Yuan Wu, Shunli Tang","doi":"10.2147/PTT.S552600","DOIUrl":"10.2147/PTT.S552600","url":null,"abstract":"<p><p>Acrodermatitis continua of Hallopeau (ACH) is a rare pustular psoriasis subtype, characterized by recurrent sterile pustules on digits, progressive nail deformation and atrophy. ACH is often refractory to different therapeutic modalities, presenting challenges in clinical practice. Emerging evidence indicates that elevated IL-17 levels modulate keratinocyte proliferation and immune cell infiltration, contributing to ACH pathogenesis and representing a promising therapeutic target. Herein, we presented a case of ACH successfully treated with vunakizumab, China's first self-developed anti-IL-17A monoclonal antibody, and reviewed publications reporting IL-17 targeted therapies for ACH, highlighting the potential benefit of IL-17 targeted therapy in ACH management.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"15 ","pages":"471-478"},"PeriodicalIF":5.2,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12476186/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145187682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Real-World Effectiveness and Drug Survival of Guselkumab in Patients with Psoriasis: A 5-Year Retrospective Study.","authors":"Edoardo Mortato, Marina Talamonti, Lorenzo Marcelli, Matteo Megna, Annunziata Raimondo, Giacomo Caldarola, Nicoletta Bernardini, Anna Balato, Anna Campanati, Maria Esposito, Claudio Bonifati, Viviana Lora, Luca Potestio, Serena Lembo, Francesco Loconsole, Eleonora De Luca, Nevena Skroza, Dario Buononato, Tommaso Bianchelli, Maria Concetta Fargnoli, Nello Tommasino, Caterina Foti, Clara De Simone, Luca Bianchi, Marco Galluzzo","doi":"10.2147/PTT.S533005","DOIUrl":"10.2147/PTT.S533005","url":null,"abstract":"<p><strong>Background: </strong>Clinical trials have demonstrated the efficacy of guselkumab in psoriasis, however, limited data are available from real-life studies evaluating the long-term effectiveness and drug survival (DS) of guselkumab.</p><p><strong>Objective: </strong>This multicenter study assessed the 5-year efficacy, DS, and predictors of treatment response in a large cohort of patients with psoriasis.</p><p><strong>Methods: </strong>In this retrospective, longitudinal study, we analyzed data from 1024 patients with moderate-to-severe psoriasis treated with guselkumab between 2019 and 2024. PASI scores were evaluated at baseline, 6 months, and 1-5 years. DS (ie, duration of continuous treatment with guselkumab without discontinuation) was assessed using Kaplan-Meier analysis, and logistic regression analysis was used to identify predictors of PASI response.</p><p><strong>Results: </strong>Mean PASI decreased from 14.3±8.8 at baseline to 1.3±2.4 at 6 months, with sustained improvement from 12-60 months (PASI values ranging from 1.0±2.2 to 1.3±3.5). Bioexperienced (ie having previous biological treatment) patients and obese individuals had lower PASI response. Subgroup analyses revealed significantly lower PASI response rates in obese patients, those previously treated with biologics, and those switched from anti-IL-17 agents (p<0.05).Multivariate logistic regression analysis revealed that previous biologic exposure and obesity remained significant negative predictors of achieving PASI 75, PASI 90, and PASI 100 across different time points. Cardiovascular disease emerged as a negative predictor for PASI 90 at 3 months (OR 0.64, 95% CI: 0.42-0.97, p=0.035). The probability of remaining on treatment at 12, 24, 36, 48, and 60 months were 95.85%, 91.73%, 89.74%, 87.08%, and 85.76% respectively. Female sex, ≥3 prior biologics, longer disease duration, and previous anti-IL-17 therapy increased the risk of treatment discontinuation. No significant differences in drug discontinuation were noted between patients with or without comorbidities.</p><p><strong>Conclusion: </strong>This real-world study demonstrates the sustained long-term efficacy and DS of guselkumab in patients with psoriasis. Prior biologic exposure, obesity, and patient history are important factors to consider when initiating treatment for long-term management.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"15 ","pages":"455-469"},"PeriodicalIF":5.2,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12449874/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145115305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}